Importer of Controlled Substances Application: Purisys, LLC, 28383-28384 [2021-11070]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 100 / Wednesday, May 26, 2021 / Notices
be found in the above-captioned
investigation. The Commission is
soliciting submissions on public interest
issues raised by the recommended relief
should the Commission find a violation.
This notice is soliciting comments from
the public only.
FOR FURTHER INFORMATION CONTACT:
Lynde Herzbach, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
205–3228. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal, telephone
202–205–1810.
SUPPLEMENTARY INFORMATION: Section
337 of the Tariff Act of 1930 provides
that, if the Commission finds a
violation, it shall exclude the articles
concerned from the United States:
unless, after considering the effect of such
exclusion upon the public health and
welfare, competitive conditions in the United
States economy, the production of like or
directly competitive articles in the United
States, and United States consumers, it finds
that such articles should not be excluded
from entry.
19 U.S.C. 1337(d)(1).
The Commission is soliciting
submissions on public interest issues
raised by the recommended relief
should the Commission find a violation,
specifically, a limited exclusion order
directed to certain tobacco heating
articles and components thereof
imported, sold for importation, and/or
sold after importation by respondents
Altria Client Services LLC and Philip
Morris USA, Inc., both of Richmond,
Virginia; and Philip Morris Products
S.A. of Neuchatel, Switzerland. Parties
are to file public interest submissions
pursuant to 19 CFR 210.50(a)(4).
The Commission is interested in
further development of the record on
the public interest in this investigation.
Accordingly, members of the public are
invited to file submissions of no more
than five (5) pages, inclusive of
attachments, concerning the public
interest in light of the ALJ’s
Recommended Determination on
Remedy and Bonding issued in this
investigation on May 14, 2021.
Comments should address whether
VerDate Sep<11>2014
20:00 May 25, 2021
Jkt 253001
issuance of the recommended remedial
orders in this investigation, should the
Commission find a violation, would
affect the public health and welfare in
the United States, competitive
conditions in the United States
economy, the production of like or
directly competitive articles in the
United States, or United States
consumers.
In particular, the Commission is
interested in comments that:
(i) Explain how the articles
potentially subject to the recommended
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the recommended orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or thirdparty suppliers have the capacity to
replace the volume of articles
potentially subject to the recommended
orders within a commercially
reasonable time; and
(v) explain how the recommended
orders would impact consumers in the
United States.
Written submissions must be filed no
later than by close of business on June
14, 2021.
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above. The Commission’s paper
filing requirements in 19 CFR 210.4(f)
are currently waived. 85 FR 15798
(March 19, 2020). Submissions should
refer to the investigation number (‘‘Inv.
No. 337–TA–1199’’) in a prominent
place on the cover page and/or the first
page. (See Handbook for Electronic
Filing Procedures, https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf.). Persons with
questions regarding filing should
contact the Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
28383
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes. All contract personnel will
sign appropriate nondisclosure
agreements. All nonconfidential written
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
Issued: May 20, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–11093 Filed 5–25–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–841]
Importer of Controlled Substances
Application: Purisys, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Purisys, LLC has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplementary Information
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 25, 2021. Such persons
may also file a written request for a
hearing on the application on or before
June 25, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
DATES:
E:\FR\FM\26MYN1.SGM
26MYN1
28384
Federal Register / Vol. 86, No. 100 / Wednesday, May 26, 2021 / Notices
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 6, 2021, Purisys,
LLC, 1550 Olympic Drive, Atlanta,
Georgia 30601–1602, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Noroxymorphone ..........
Drug
code
Schedule
9668
II
The company plans to use as
reference standards for analytical and
research purposes for their customers.
No other activity for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–11070 Filed 5–25–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
issuance of the proposed registration on
or before June 25, 2021. Such persons
may also file a written request for a
hearing on the application on or before
June 25, 2021.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on April 30, 2021, Almac
Clinical Services Incorp, (ACSI) 25 Fretz
Road, Souderton, Pennsylvania 18964,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Psilocybin .....................
Oxycodone ...................
Hydromorphone ............
Morphine .......................
Noroxymorphone ..........
Tapentadol ....................
Fentanyl ........................
Drug
code
7437
9143
9150
9330
9668
9780
9801
[Docket No. DEA–840]
Importer of Controlled Substances
Application: Almac Clinical Services
Incorp. (ACSI)
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Almac Clinical Services
Incorp. (ACSI) has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplementary Information
listed below for further drug
information.
SUMMARY:
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–11069 Filed 5–25–21; 8:45 am]
BILLING CODE P
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
DATES:
20:00 May 25, 2021
Jkt 253001
I
II
II
II
II
II
II
The company plans to import the
listed finished dosage unit products
controlled substances in dosage form to
conduct clinical trials. Approval of
permit applications will occur only
when the registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to import of the Food
and Drug Administration-approved or
non-approved finished dosage forms for
commercial sale.
Drug Enforcement Administration
VerDate Sep<11>2014
Schedule
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
DEPARTMENT OF LABOR
Employment and Training
Administration
Workforce Innovation and Opportunity
Act; Native American Employment and
Training Council
Employment and Training
Administration, U.S. Department of
Labor.
ACTION: Notice of meeting.
AGENCY:
Pursuant to the Federal
Advisory Committee Act (FACA), and
the Workforce Innovation and
Opportunity Act (WIOA), notice is
hereby given of the next meeting of the
Native American Employment and
Training Council (Council), as
constituted under WIOA.
DATES: The meeting will begin at 12:00
p.m., (Eastern Daylight Time) on
Tuesday, June 15, 2021, and continue
until 4:30 p.m. The meeting will
reconvene at 12:00 p.m., on Wednesday,
June 16, 2021 and adjourn at 4:30 p.m.
The period from 3:00 p.m., to 4:00 p.m.,
on June 16, 2021 is reserved for
participation and comment by members
of the public.
ADDRESSES: The meeting will be held
virtually on the Zoom.gov platform. To
join the meeting use the following:
https://www.zoomgov.com/j/
1613101548?pwd=dDBXQk1Uc2ht
NGZYR08rQ0s4VXB5QT09.
Meeting ID: 161 310 1548.
Passcode: 513970.
Dial in number: +1 (551) 285–1373.
SUPPLEMENTARY INFORMATION: Council
members and members of the public are
encouraged to logon to Zoom.gov early
to allow for connection issues and
troubleshooting.
Security Instructions: Meeting
participants should use the link and dial
in instructions provided in ADDRESSES.
The meeting will be open to the
public.
Members of the public not present
may submit a written statement by
Thursday, June 11, 2021, to be included
in the record of the meeting. Statements
are to be submitted to Athena R. Brown,
Designated Federal Officer (DFO), U.S.
Department of Labor at brown.athena@
dol.gov. Persons who need special
accommodations should contact Suzie
Casal at (703) 967–1829 or casal.suzie@
dol.gov, at least two business days
before the meeting. The formal agenda
will focus on the following topics: (1)
Update of National Congress of
American Indians policy
recommendations, (2) PY 2021/2022
training and technical assistance
priorities, (3) update on Indian and
SUMMARY:
E:\FR\FM\26MYN1.SGM
26MYN1
]]>Agencies
[Federal Register Volume 86, Number 100 (Wednesday, May 26, 2021)]
[Notices]
[Pages 28383-28384]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11070]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-841]
Importer of Controlled Substances Application: Purisys, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Purisys, LLC has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to Supplementary
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before June 25, 2021.
Such persons may also file a written request for a hearing on the
application on or before June 25, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator,
[[Page 28384]]
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement Administration, Attn: DEA Federal
Register Representative/DPW, 8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 6, 2021, Purisys, LLC, 1550 Olympic Drive,
Atlanta, Georgia 30601-1602, applied to be registered as an importer of
the following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Noroxymorphone......................... 9668 II
------------------------------------------------------------------------
The company plans to use as reference standards for analytical and
research purposes for their customers. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-11070 Filed 5-25-21; 8:45 am]
BILLING CODE P
